US Patent Application 18022565. SELECTION OF A DOSE FOR RADIOTHERAPY OF A PROSTATE CANCER SUBJECT simplified abstract
Contents
SELECTION OF A DOSE FOR RADIOTHERAPY OF A PROSTATE CANCER SUBJECT
Organization Name
Inventor(s)
RALF DIETER Hoffmann of BRUEGGEN (DE)
MONIQUE Stoffels of EINDHOVEN (NL)
SELECTION OF A DOSE FOR RADIOTHERAPY OF A PROSTATE CANCER SUBJECT - A simplified explanation of the abstract
This abstract first appeared for US patent application 18022565 titled 'SELECTION OF A DOSE FOR RADIOTHERAPY OF A PROSTATE CANCER SUBJECT
Simplified Explanation
The patent application describes a method for selecting the appropriate dose of radiotherapy for prostate cancer patients. This method involves analyzing the gene expression profiles of immune defense response genes, T-Cell receptor signaling genes, and PDE4D7 correlated genes in a biological sample obtained from the patient. Based on these gene expression profiles, the radiotherapy dose is determined. The selection or therapy recommendation based on this dose can then be provided to the medical caregiver or the patient.
- Method for selecting the appropriate radiotherapy dose for prostate cancer patients
- Analyzes gene expression profiles of immune defense response genes, T-Cell receptor signaling genes, and PDE4D7 correlated genes
- Determines the radiotherapy dose based on the gene expression profiles
- Provides selection or therapy recommendation to the medical caregiver or patient
Original Abstract Submitted
The invention relates to a method of selecting a dose for radiotherapy of a prostate cancer subject, comprising determining or receiving the result of a determination of a first gene expression profile for each of one or more immune defense response genes, and/or of a second gene expression profile for each of one or more T-Cell receptor signaling genes, and/or of a third gene expression profile for each of one or more PDE4D7 correlated genes, said first, second and third expression profile(s) being determined in a biological sample obtained from the subject, selecting the radiotherapy dose based on the first gene expression profile(s), or on the second gene expression profile(s), or on the third gene expression profile(s), or on the first, second, and third gene expression profile(s), and, optionally, providing the selection or a therapy recommendation based on the selection to a medical caregiver or the subject.
